[go: up one dir, main page]

MX2019004707A - Reestimulacion de linfocitos infiltrantes de tumor crioconservados. - Google Patents

Reestimulacion de linfocitos infiltrantes de tumor crioconservados.

Info

Publication number
MX2019004707A
MX2019004707A MX2019004707A MX2019004707A MX2019004707A MX 2019004707 A MX2019004707 A MX 2019004707A MX 2019004707 A MX2019004707 A MX 2019004707A MX 2019004707 A MX2019004707 A MX 2019004707A MX 2019004707 A MX2019004707 A MX 2019004707A
Authority
MX
Mexico
Prior art keywords
stimulation
cryoconserved
infiltrating tumor
tumor lymphocytes
lymphocytes
Prior art date
Application number
MX2019004707A
Other languages
English (en)
Inventor
Frank Ian
T Lotze Michael
Original Assignee
Iovance Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Iovance Biotherapeutics Inc filed Critical Iovance Biotherapeutics Inc
Publication of MX2019004707A publication Critical patent/MX2019004707A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/16—Physical preservation processes
    • A01N1/162—Temperature processes, e.g. following predefined temperature changes over time
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/04—Immunosuppressors, e.g. cyclosporin, tacrolimus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1121—Dendritic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1157—Monocytes, macrophages
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/99—Coculture with; Conditioned medium produced by genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)

Abstract

La presente invención se refiere a métodos para re-estimular las poblaciones de TIL que conducen a fenotipo mejorado y salud metabólica incrementada de los TIL y proporcionar métodos para evaluar para poblaciones de TIL para determinar la adecuabilidad para infusiones más eficaces después de la re-estimulación.
MX2019004707A 2016-10-26 2017-10-26 Reestimulacion de linfocitos infiltrantes de tumor crioconservados. MX2019004707A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662413387P 2016-10-26 2016-10-26
US201662413283P 2016-10-26 2016-10-26
US201662415452P 2016-10-31 2016-10-31
PCT/US2017/058610 WO2018081473A1 (en) 2016-10-26 2017-10-26 Restimulation of cryopreserved tumor infiltrating lymphocytes

Publications (1)

Publication Number Publication Date
MX2019004707A true MX2019004707A (es) 2019-08-12

Family

ID=60327390

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019004707A MX2019004707A (es) 2016-10-26 2017-10-26 Reestimulacion de linfocitos infiltrantes de tumor crioconservados.
MX2024004500A MX2024004500A (es) 2016-10-26 2019-04-23 Reestimulacion de linfocitos infiltrantes de tumor crioconservados.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2024004500A MX2024004500A (es) 2016-10-26 2019-04-23 Reestimulacion de linfocitos infiltrantes de tumor crioconservados.

Country Status (24)

Country Link
US (22) US11026974B2 (es)
EP (2) EP3532607B1 (es)
JP (3) JP2019532652A (es)
KR (2) KR20190066073A (es)
CN (1) CN110099998A (es)
AU (1) AU2017347851B2 (es)
BR (1) BR112019008305A2 (es)
CA (1) CA3041678A1 (es)
DK (1) DK3532607T3 (es)
ES (1) ES2977118T3 (es)
FI (1) FI3532607T3 (es)
HR (1) HRP20240436T1 (es)
HU (1) HUE066460T2 (es)
IL (1) IL266209B2 (es)
LT (1) LT3532607T (es)
MD (1) MD3532607T2 (es)
MX (2) MX2019004707A (es)
PL (1) PL3532607T3 (es)
PT (1) PT3532607T (es)
RS (1) RS65448B1 (es)
SG (1) SG11201903331QA (es)
SI (1) SI3532607T1 (es)
SM (1) SMT202400133T1 (es)
WO (1) WO2018081473A1 (es)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201522097D0 (en) 2015-12-15 2016-01-27 Cellular Therapeutics Ltd Cells
ES3000676T3 (en) 2016-07-07 2025-03-03 Iovance Biotherapeutics Inc Programmed death 1 ligand 1 (pd-l1) binding proteins and methods of use thereof
MX2019004707A (es) 2016-10-26 2019-08-12 Iovance Biotherapeutics Inc Reestimulacion de linfocitos infiltrantes de tumor crioconservados.
TWI788307B (zh) 2016-10-31 2023-01-01 美商艾歐凡斯生物治療公司 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
US11401507B2 (en) 2016-11-17 2022-08-02 Iovance Biotherapeutics, Inc. Remnant tumor infiltrating lymphocytes and methods of preparing and using the same
WO2018129336A1 (en) 2017-01-06 2018-07-12 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof
GB201700621D0 (en) 2017-01-13 2017-03-01 Guest Ryan Dominic Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue
US11254913B1 (en) 2017-03-29 2022-02-22 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
JOP20190224A1 (ar) 2017-03-29 2019-09-26 Iovance Biotherapeutics Inc عمليات من أجل إنتاج الخلايا اللمفاوية المرتشحة للأورام واستخداماتها في العلاج المناعي
MX2019014023A (es) 2017-05-24 2020-02-17 Novartis Ag Proteinas de anticuerpo injertadas con citocina y metodos de uso en el tratamiento del cancer.
TW201919662A (zh) 2017-06-05 2019-06-01 美商艾歐凡斯生物治療公司 對雙重難治性黑色素瘤使用腫瘤浸潤性淋巴細胞之方法
BR112020009663A2 (pt) * 2017-11-17 2020-11-10 Iovance Biotherapeutics, Inc. método para a expansão de linfócitos infiltrantes de tumor (tils) em uma população terapêutica de tils, método para o tratamento de um indivíduo com câncer, composição
US11713446B2 (en) 2018-01-08 2023-08-01 Iovance Biotherapeutics, Inc. Processes for generating TIL products enriched for tumor antigen-specific T-cells
SG11202006541UA (en) 2018-01-08 2020-08-28 Iovance Biotherapeutics Inc Processes for generating til products enriched for tumor antigen-specific t-cells
BR112020018658A2 (pt) 2018-03-15 2020-12-29 KSQ Therapeutics, Inc. Composições de regulação gênica e métodos para imu-noterapia aprimorada
MA52533A (fr) 2018-04-27 2021-03-03 Iovance Biotherapeutics Inc Procédé en circuit fermé pour l'amplification et l'edition de gènes de lymphocytes d'infiltration des tumeurs et leurs utilisations en immunothérapie
US12473532B2 (en) 2018-05-10 2025-11-18 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
TW202031273A (zh) * 2018-08-31 2020-09-01 美商艾歐凡斯生物治療公司 抗ｐｄ－１抗體難治療性之非小細胞肺癌（ｎｓｃｌｃ）病患的治療
AU2019342749B2 (en) * 2018-09-20 2025-07-10 Iovance Biotherapeutics, Inc. Expansion of tils from cryopreserved tumor samples
CN113412259B (zh) 2018-10-15 2024-07-16 紐力克斯治疗公司 通过泛素蛋白酶体途径降解btk的双官能化合物
JP2022506508A (ja) 2018-11-05 2022-01-17 アイオバンス バイオセラピューティクス，インコーポレイテッド Ａｋｔ経路阻害剤を利用したｔｉｌの拡大培養
CA3118634A1 (en) 2018-11-05 2020-05-14 Iovance Biotherapeutics, Inc. Treatment of nsclc patients refractory for anti-pd-1 antibody
BR112021008266A2 (pt) * 2018-11-05 2022-01-04 Iovance Biotherapeutics Inc Métodos para expandir linfócitos infiltrantes de tumor em uma população terapêutica de linfócitos infiltrantes de tumor e para tratar um sujeito com câncer, e, população terapêutica de linfócitos infiltrantes de tumor
KR20210091213A (ko) 2018-11-05 2021-07-21 이오반스 바이오테라퓨틱스, 인크. 종양 침윤 림프구의 생성 방법 및 면역치료법에서 이의 용도
EP3898949A1 (en) 2018-12-19 2021-10-27 Iovance Biotherapeutics, Inc. Methods of expanding tumor infiltrating lymphocytes using engineered cytokine receptor pairs and uses thereof
WO2020180733A1 (en) * 2019-03-01 2020-09-10 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
WO2020232029A1 (en) 2019-05-13 2020-11-19 Iovance Biotherapeutics, Inc. Methods and compositions for selecting tumor infiltrating lymphocytes and uses of the same in immunotherapy
GB201911066D0 (en) 2019-08-02 2019-09-18 Achilles Therapeutics Ltd T cell therapy
AU2020397920A1 (en) 2019-12-04 2022-06-16 Nurix Therapeutics, Inc. Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway
WO2021118990A1 (en) * 2019-12-11 2021-06-17 Iovance Biotherapeutics, Inc. Processes for the production of tumor infiltrating lymphocytes (tils) and methods of using the same
CN115244173A (zh) 2019-12-20 2022-10-25 英研生物(英国)有限公司 用于分离肿瘤浸润淋巴细胞的装置及方法及其用途
WO2021146487A2 (en) 2020-01-14 2021-07-22 Synthekine, Inc. Il2 orthologs and methods of use
AU2021226903A1 (en) * 2020-02-27 2022-10-20 Turnstone Biologics Corp. Methods for ex vivo enrichment and expansion of tumor reactive T cells and related compositions thereof
EP3892720A1 (en) 2020-04-06 2021-10-13 Innovative Cellular Therapeutics Holdings, Ltd. Presenting cell and use thereof in cell therapy
US12159700B2 (en) 2020-04-22 2024-12-03 Iovance Biotherapeutics, Inc. Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy
CN115461062A (zh) 2020-04-28 2022-12-09 阿基里斯治疗英国有限公司 T细胞疗法
BR112022021551A2 (pt) 2020-04-28 2023-01-03 Lyell Immunopharma Inc Métodos para cultivar células
AU2021264068A1 (en) * 2020-04-30 2022-12-08 The Translational Genomics Research Institute Neoantigen-informed tumor-infiltrating lymphocyte cancer immunotherapy
US20230293685A1 (en) 2020-05-04 2023-09-21 Iovance Biotherapeutics, Inc. Selection of improved tumor reactive t-cells
WO2021226061A1 (en) 2020-05-04 2021-11-11 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy
CN115698267A (zh) 2020-05-29 2023-02-03 上海君赛生物科技有限公司 肿瘤浸润淋巴细胞的种子细胞培养基及其应用
CA3196823A1 (en) * 2020-09-24 2022-03-31 The Jackson Laboratory Humanized mouse models for assessing immune cell therapy
WO2022076606A1 (en) 2020-10-06 2022-04-14 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
US20230372397A1 (en) 2020-10-06 2023-11-23 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
WO2022105816A1 (zh) * 2020-11-19 2022-05-27 苏州沙砾生物科技有限公司 肿瘤浸润淋巴细胞的培养方法及其用途
WO2022125941A1 (en) 2020-12-11 2022-06-16 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with braf inhibitors and/or mek inhibitors
US20240123067A1 (en) 2020-12-17 2024-04-18 Iovance Biotherapeutics, Inc. Treatment of cancers with tumor infiltrating lymphocyte therapies
CA3202483A1 (en) 2020-12-17 2022-06-23 Maria Fardis Treatment with tumor infiltrating lymphocyte therapies in combination with ctla-4 and pd-1 inhibitors
CN114686430A (zh) * 2020-12-31 2022-07-01 上海赛比曼生物科技有限公司 一种制备til的方法
CA3206549A1 (en) 2021-01-29 2022-08-04 Frederick G. Vogt Methods of making modified tumor infiltrating lymphocytes and their use in adoptive cell therapy
EP4288140A1 (en) 2021-02-05 2023-12-13 Iovance Biotherapeutics, Inc. Adjuvant therapy for cancer
JP2024510505A (ja) 2021-03-19 2024-03-07 アイオバンス バイオセラピューティクス，インコーポレイテッド Ｃｄ３９／ｃｄ６９選択に関連した腫瘍浸潤リンパ球（ｔｉｌ）拡張及びｔｉｌにおける遺伝子ノックアウトのための方法
IL306072A (en) 2021-03-25 2023-11-01 Iovance Biotherapeutics Inc Methods and preparations for T-cell coculture potency assays and use with cellular therapy products
US20240210396A1 (en) 2021-04-09 2024-06-27 Achilles Therapeutics Uk Limited Batch release assay for pharmaceutical products relating to t cell therapies
GB202109886D0 (en) 2021-07-08 2021-08-25 Achilles Therapeutics Uk Ltd Assay
EP4326287A2 (en) 2021-04-19 2024-02-28 Iovance Biotherapeutics, Inc. Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
JP2024519029A (ja) 2021-05-17 2024-05-08 アイオバンス バイオセラピューティクス，インコーポレイテッド Ｐｄ－１遺伝子編集された腫瘍浸潤リンパ球及び免疫療法におけるその使用
WO2022269250A1 (en) 2021-06-22 2022-12-29 Achilles Therapeutics Uk Limited A method for producing antigen-specific t cells
AR126198A1 (es) * 2021-06-24 2023-09-27 Instil Bio Inc Procesamiento de linfocitos infiltrantes de tumores
JP2024526898A (ja) 2021-07-22 2024-07-19 アイオバンス バイオセラピューティクス，インコーポレイテッド 固形腫瘍断片の凍結保存のための方法
CA3226942A1 (en) 2021-07-28 2023-02-02 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with kras inhibitors
US20240358835A1 (en) * 2021-08-17 2024-10-31 Orgenesis Inc. Tumor infiltrating lymphocytes with increased metabolic activity
WO2023039488A1 (en) 2021-09-09 2023-03-16 Iovance Biotherapeutics, Inc. Processes for generating til products using pd-1 talen knockdown
JP2024542984A (ja) 2021-10-26 2024-11-19 ニューリックス セラピューティクス，インコーポレイテッド がんを治療および予防するためのピペリジニルピラジン－カルボキサミド化合物、およびｂｔｋを分解するためのピペリジニルピラジン－カルボキサミド化合物
EP4423755A2 (en) 2021-10-27 2024-09-04 Iovance Biotherapeutics, Inc. Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy
AU2022388729A1 (en) 2021-11-10 2024-05-16 Iovance Biotherapeutics, Inc. Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes
US20250082777A1 (en) 2022-01-10 2025-03-13 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
JP2025504908A (ja) 2022-01-28 2025-02-19 アイオバンス バイオセラピューティクス，インコーポレイテッド サイトカイン関連腫瘍浸潤リンパ球組成物及び方法
WO2023147486A1 (en) 2022-01-28 2023-08-03 Iovance Biotherapeutics, Inc. Tumor infiltrating lymphocytes engineered to express payloads
WO2023193015A1 (en) 2022-04-01 2023-10-05 Sana Biotechnology, Inc. Cytokine receptor agonist and viral vector combination therapies
EP4504220A1 (en) 2022-04-06 2025-02-12 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
EP4507704A1 (en) 2022-04-15 2025-02-19 Iovance Biotherapeutics, Inc. Til expansion processes using specific cytokine combinations and/or akti treatment
EP4522202A1 (en) 2022-05-10 2025-03-19 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with an il-15r agonist
EP4565683A1 (en) 2022-08-01 2025-06-11 Iovance Biotherapeutics, Inc. Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
EP4583889A1 (en) 2022-09-09 2025-07-16 Iovance Biotherapeutics, Inc. Processes for generating til products using pd-1/tigit talen double knockdown
WO2024055018A1 (en) 2022-09-09 2024-03-14 Iovance Biotherapeutics, Inc. Processes for generating til products using pd-1/tigit talen double knockdown
WO2024098027A1 (en) 2022-11-04 2024-05-10 Iovance Biotherapeutics, Inc. Methods for tumor infiltrating lymphocyte (til) expansion related to cd39/cd103 selection
EP4623072A2 (en) 2022-11-21 2025-10-01 Iovance Biotherapeutics, Inc. Two-dimensional processes for the expansion of tumor infiltrating lymphocytes and therapies therefrom
WO2024112711A2 (en) 2022-11-21 2024-05-30 Iovance Biotherapeutics, Inc. Methods for assessing proliferation potency of gene-edited t cells
WO2024118836A1 (en) 2022-11-30 2024-06-06 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes with shortened rep step
WO2025054540A1 (en) 2023-09-08 2025-03-13 Iovance Biotherapeutics, Inc. Methods of gene-editing using programmable nucleases
WO2025101484A1 (en) 2023-11-06 2025-05-15 Iovance Biotherapeutics, Inc. Treatment of endometrial cancers with tumor infiltrating lymphocyte therapies

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
AU7873187A (en) 1986-08-08 1988-02-24 University Of Minnesota Method of culturing leukocytes
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US7479269B2 (en) 1988-11-23 2009-01-20 Genetics Institute, Llc Methods for selectively enriching TH1 and TH2 cells
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US4902502A (en) 1989-01-23 1990-02-20 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
US5089261A (en) 1989-01-23 1992-02-18 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
US5126132A (en) 1989-08-21 1992-06-30 The United States Of America As Represented By The Department Of Health And Human Services Tumor infiltrating lymphocytes as a treatment modality for human cancer
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
JP2004534721A (ja) 2000-10-31 2004-11-18 ピーアール ファーマシューティカルズ，インク． 生理活性分子の向上した送達のための方法及び組成物
US20050084967A1 (en) 2002-06-28 2005-04-21 Xcyte Therapies, Inc. Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
JP2006506987A (ja) 2002-06-28 2006-03-02 エクサイト セラピーズ インコーポレーティッド 自己免疫および臓器または造血幹細胞移植に関連する免疫学的欠損を有する患者における免疫レパートリー回復のための組成物および方法
CA2497552C (en) 2002-09-06 2014-05-27 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Immunotherapy with in vitro-selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy
ITMI20022118A1 (it) 2002-10-04 2004-04-05 Abiogen Pharma Spa Procedimento per la coltura su larga scala di t-linfociti in un sistema omogeneo.
EP3450538B1 (en) 2003-10-08 2021-08-25 Wilson Wolf Manufacturing Corporation Cell culture methods and devices utilizing gas permeable materials
PL2161336T5 (pl) 2005-05-09 2017-10-31 Ono Pharmaceutical Co Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi
CN104356236B (zh) 2005-07-01 2020-07-03 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1(pd-l1)的人单克隆抗体
CA2634169C (en) 2005-12-21 2012-11-27 Sentoclone Ab Method for treating disseminated cancer
WO2007071409A1 (en) 2005-12-21 2007-06-28 Sentoclone Ab Method for treating colon cancer
AU2006328945B2 (en) 2005-12-21 2011-06-30 Sentoclone International Ab Method for treating malignant melanoma
WO2007071388A1 (en) 2005-12-21 2007-06-28 Sentoclone Ab Improved method for expansion of tumour-reactive t-lymphocytes for immunotherapy of patients with cancer
US7951365B2 (en) 2007-06-27 2011-05-31 Deifiera Falun Ab Method for expansion of tumour-reactive T-lymphocytes for immunotherapy of patients with specific cancer types
EP2203746B1 (en) 2007-09-24 2013-03-06 Technion Research & Development Foundation Ltd. T cell subpopulations capable of treating cancer
US20150320798A1 (en) 2012-11-27 2015-11-12 The Johns Hopkins University Use of Post-Transplant Cyclophosphamide Treated Allogeneic Marrow Infiltrating Lymphocytes to Augment Anti-Tumor Immunity
US8383099B2 (en) 2009-08-28 2013-02-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adoptive cell therapy with young T cells
US8956860B2 (en) 2009-12-08 2015-02-17 Juan F. Vera Methods of cell culture for adoptive cell therapy
EP2698430A3 (en) 2009-12-08 2014-03-05 Wilson Wolf Manufacturing Corporation Methods of cell culture for adoptive cell therapy
US20130115617A1 (en) 2009-12-08 2013-05-09 John R. Wilson Methods of cell culture for adoptive cell therapy
KR20200070407A (ko) 2010-11-12 2020-06-17 넥타르 테라퓨틱스 Ｉｌ-2 부분 및 중합체의 접합체
WO2012129201A1 (en) 2011-03-22 2012-09-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
US9476028B2 (en) 2011-04-13 2016-10-25 Immunicum Ab Method for proliferation of antigen-specific T cells
DK2768939T3 (en) 2011-10-21 2016-11-07 Cell Medica Ltd Device for aseptic expansion of cells
GB201121308D0 (en) 2011-12-12 2012-01-25 Cell Medica Ltd Process
CN102816734A (zh) 2012-05-09 2012-12-12 阮润生 一种肿瘤抗原特异性t细胞的获取方法
EP2850175B1 (en) 2012-05-18 2020-12-16 Wilson Wolf Manufacturing Corporation Improved methods of cell culture for adoptive cell therapy
AU2013274416B2 (en) 2012-06-11 2019-07-04 Wilson Wolf Manufacturing, LLC Improved methods of cell culture for adoptive cell therapy
EP2925329B1 (en) 2012-11-27 2021-01-06 Borrello, Ivan Marques Use of post-transplant cyclophosphamide treated allogeneic marrow infiltrating lymphocytes to augment anti-tumor immunity
US9844569B2 (en) 2013-03-01 2017-12-19 The United State Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of producing enriched populations of tumor reactive T cells from peripheral blood
JP6416131B2 (ja) 2013-03-01 2018-10-31 アメリカ合衆国 濃縮された腫瘍反応性ｔ細胞集団を腫瘍から作製する方法
CN103396991A (zh) * 2013-05-02 2013-11-20 陈晚华 一种快速高效扩增肿瘤浸润性淋巴细胞的方法
CN118562610A (zh) 2013-06-24 2024-08-30 威尔逊沃夫制造公司 用于透气性细胞培养过程的封闭系统装置和方法
CN105452448B (zh) 2013-07-15 2020-07-28 美国卫生和人力服务部 制备抗人乳头瘤病毒抗原的t细胞的方法
US10233425B2 (en) 2013-09-16 2019-03-19 The Trustees Of The University Of Pennsylvania CD137 enrichment for efficient tumor infiltrating lymphocyte selection
MX374472B (es) 2014-03-20 2025-03-06 H Lee Moffitt Cancer Ct & Res Composiciones y métodos para mejorar los linfocitos infiltrantes de tumor para terapia celular adoptiva.
ES2980788T3 (es) 2014-04-10 2024-10-03 H Lee Moffitt Cancer Ct & Res Expansión mejorada de linfocitos infiltrantes de tumores para terapia celular adoptiva
KR102441940B1 (ko) 2014-06-11 2022-09-08 폴리바이오셉트 게엠베하 시토킨 조성물을 이용한 능동 세포적 면역 치료법을 위한 림프구의 증식
EP4270006A3 (en) 2014-06-13 2024-01-10 Immudex ApS General detection and isolation of specific cells by binding of labeled molecules
PT3188740T (pt) 2014-09-04 2021-06-23 Univ Johns Hopkins Ativação de linfócitos infiltrantes de medula em condições hipóxicas em alternância com normóxicas
EP3200818B1 (en) 2014-10-02 2022-06-08 The United States of America, as represented by the Secretary, Department of Health and Human Services Methods of isolating t cell receptors having antigenic specificity for a cancer-specific mutation
EP3034092A1 (en) * 2014-12-17 2016-06-22 Université de Lausanne Adoptive immunotherapy for treating cancer
AU2016258845B2 (en) 2015-05-01 2022-03-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of isolating T cells and T cell receptors having antigenic specificity for a cancer-specific mutation from peripheral blood
FR3040396A1 (fr) 2015-06-30 2017-03-03 Chu Nantes Procede de cryoconservation de lymphocytes infiltrant la tumeur
FR3038324B1 (fr) 2015-06-30 2020-10-30 Lab Francais Du Fractionnement Procede de cryoconservation de cellules a visee therapeutique
WO2017048614A1 (en) 2015-09-15 2017-03-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of isolating tumor-reactive t cell receptors from tumor or peripheral blood
MA45488A (fr) 2015-10-22 2018-08-29 Juno Therapeutics Gmbh Procédés, kits et appareil de culture de cellules
JP7084304B2 (ja) 2015-10-28 2022-06-14 ライフ テクノロジーズ エーエス 細胞表面シグナル及びシグナル比を変えることによる、異なるｔ細胞亜集団の選択的増殖の方法
CN105602901B (zh) * 2016-03-11 2020-01-31 广州赛莱拉干细胞科技股份有限公司 生物反应器及其搅拌桨和使用其培养til细胞的方法
AU2017290119A1 (en) 2016-06-28 2019-01-24 Geneius Biotechnology, Inc. T cell compositions for immunotherapy
CN106244538A (zh) 2016-08-04 2016-12-21 英普乐孚生物技术(上海)有限公司 一种恶性腹水来源的til细胞的分离培养方法
MX2019002946A (es) 2016-09-14 2019-09-26 Abbvie Biotherapeutics Inc Anticuerpos anti-pd-1 y sus usos.
MX2019004707A (es) 2016-10-26 2019-08-12 Iovance Biotherapeutics Inc Reestimulacion de linfocitos infiltrantes de tumor crioconservados.
TWI788307B (zh) 2016-10-31 2023-01-01 美商艾歐凡斯生物治療公司 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
US11401507B2 (en) * 2016-11-17 2022-08-02 Iovance Biotherapeutics, Inc. Remnant tumor infiltrating lymphocytes and methods of preparing and using the same
WO2018102761A1 (en) 2016-12-02 2018-06-07 City Of Hope Methods for manufacturing and expanding t cells expressing chimeric antigen receptors and other receptors
CN106591232A (zh) 2017-01-04 2017-04-26 安徽安龙基因医学检验所有限公司 一种高效的pd‑1‑cd8+t细胞的培养方法
WO2018129336A1 (en) * 2017-01-06 2018-07-12 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof
AU2018205234B2 (en) 2017-01-06 2024-09-19 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes (TILs) with tumor necrosis factor receptor superfamily (TNFRSF) agonists and therapeutic combinations of TILs and TNFRSF agonists
KR102771581B1 (ko) 2017-03-14 2025-02-25 주노 쎄러퓨티크스 인코퍼레이티드 극저온 보관 방법
JOP20190224A1 (ar) * 2017-03-29 2019-09-26 Iovance Biotherapeutics Inc عمليات من أجل إنتاج الخلايا اللمفاوية المرتشحة للأورام واستخداماتها في العلاج المناعي
US11254913B1 (en) * 2017-03-29 2022-02-22 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
MX2019013202A (es) 2017-05-10 2020-01-21 Iovance Biotherapeutics Inc Expansion de linfocitos de infiltracion de tumor a partir de tumores liquidos y usos terapeuticos de los mismos.
TW201919662A (zh) 2017-06-05 2019-06-01 美商艾歐凡斯生物治療公司 對雙重難治性黑色素瘤使用腫瘤浸潤性淋巴細胞之方法
CN107384867B (zh) 2017-08-04 2020-09-11 北京世纪劲得生物技术有限公司 一种肿瘤组织til细胞制备方法及专用培养基
US11713446B2 (en) 2018-01-08 2023-08-01 Iovance Biotherapeutics, Inc. Processes for generating TIL products enriched for tumor antigen-specific T-cells
US12159700B2 (en) * 2020-04-22 2024-12-03 Iovance Biotherapeutics, Inc. Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy
US11918517B2 (en) * 2021-10-07 2024-03-05 Stryker Corporation Cover systems for blocking apertures of patient support apparatuses

Also Published As

Publication number Publication date
US11351199B2 (en) 2022-06-07
US20220395534A1 (en) 2022-12-15
US20220133798A1 (en) 2022-05-05
US11857573B2 (en) 2024-01-02
US11304980B2 (en) 2022-04-19
DK3532607T3 (da) 2024-04-02
CA3041678A1 (en) 2018-05-03
US11344581B2 (en) 2022-05-31
US20220000927A1 (en) 2022-01-06
KR20190066073A (ko) 2019-06-12
MX2024004500A (es) 2024-05-06
US20210252062A1 (en) 2021-08-19
IL266209B1 (en) 2024-10-01
EP3532607B1 (en) 2024-01-31
US11266694B2 (en) 2022-03-08
MD3532607T2 (ro) 2024-07-31
JP2019532652A (ja) 2019-11-14
US20220088080A1 (en) 2022-03-24
PL3532607T3 (pl) 2024-07-01
SG11201903331QA (en) 2019-05-30
US11969444B2 (en) 2024-04-30
KR20240150531A (ko) 2024-10-15
US11364266B2 (en) 2022-06-21
US11058728B1 (en) 2021-07-13
US20210260121A1 (en) 2021-08-26
US11865140B2 (en) 2024-01-09
IL266209A (en) 2019-06-30
US11179419B2 (en) 2021-11-23
WO2018081473A1 (en) 2018-05-03
IL266209B2 (en) 2025-02-01
ES2977118T3 (es) 2024-08-21
RS65448B1 (sr) 2024-05-31
AU2017347851A1 (en) 2019-05-02
US11344580B2 (en) 2022-05-31
AU2017347851B2 (en) 2024-03-07
US20210401889A1 (en) 2021-12-30
US10517894B2 (en) 2019-12-31
US11141438B2 (en) 2021-10-12
US20220000929A1 (en) 2022-01-06
BR112019008305A2 (pt) 2019-08-06
US11351198B2 (en) 2022-06-07
US20220000926A1 (en) 2022-01-06
US11026974B2 (en) 2021-06-08
LT3532607T (lt) 2024-05-10
HRP20240436T1 (hr) 2024-06-21
CN110099998A (zh) 2019-08-06
US20220387501A1 (en) 2022-12-08
EP3532607A1 (en) 2019-09-04
HUE066460T2 (hu) 2024-08-28
US20200299644A1 (en) 2020-09-24
US20220000928A1 (en) 2022-01-06
US20210252063A1 (en) 2021-08-19
US20230030883A1 (en) 2023-02-02
US12188048B2 (en) 2025-01-07
US20220088081A1 (en) 2022-03-24
JP2023126265A (ja) 2023-09-07
EP4180520A1 (en) 2023-05-17
US20220096555A1 (en) 2022-03-31
US11123371B2 (en) 2021-09-21
US11311578B2 (en) 2022-04-26
SI3532607T1 (sl) 2024-06-28
US20220387500A1 (en) 2022-12-08
US20180228841A1 (en) 2018-08-16
US11975028B2 (en) 2024-05-07
US20220378837A1 (en) 2022-12-01
PT3532607T (pt) 2024-05-02
US11351197B2 (en) 2022-06-07
FI3532607T3 (fi) 2024-03-15
SMT202400133T1 (it) 2024-05-14
JP2026012189A (ja) 2026-01-23
US11369637B2 (en) 2022-06-28
US20220378834A1 (en) 2022-12-01
US20220008470A1 (en) 2022-01-13

Similar Documents

Publication Publication Date Title
MX2019004707A (es) Reestimulacion de linfocitos infiltrantes de tumor crioconservados.
IL291035A (en) Automatic article enrichment by social media trends
IL269440B (en) Closed systems for use in selecting immune cell populations for adoptive therapy
CO2018012699A2 (es) Anticuerpos anti-cd40 y sus usos
MX2017002667A (es) Metodo para producir celulas progenitoras hepaticas adultas.
CL2016001708A1 (es) Determinantes de respuesta del cáncer a la inmunoterapia
EP3356526A4 (en) COMPREHENSIVE IN-VITRO MESSAGE OF CREATING EVENTS BY SEQUENCING (CIRCLE-SEQ)
CR20160500A (es) Anticuerpos anti-ox40 y métodos de uso
CR20170514A (es) Combinaciones herbicidas que comprenden l-glufosinato e indiziflam.
SA516380552B1 (ar) طرق وأنظمة لتقدير أحجام وتأثيرات عوائق حفر بئر في آبار حقن بالماء
AU357418S (en) Chair
MX2019000232A (es) Deteccion de flujo de fluidos.
MX380491B (es) Composición farmaceutica que comprende un modulador de gibspla2 y usos de la misma.
MX2023006416A (es) Anticuerpos, usos y metodos.
SG11201701223WA (en) Systems and methods for identifying merchant locations based on transaction records
BR112017006419A2 (pt) medições cinéticas de tau
CR20170491A (es) Combinaciones herbicidas que comprenden glufosinato e indaziflam.
CO2018007621A2 (es) Composiciones y métodos para evaluar el riesgo de ocurrencia de cáncer
IL248080A0 (en) System and method for identifying sources associated with biological arrhythmias
CL2015002924A1 (es) Plantas de brassica que comprenden alelos de da1 mutantes
FR3034753B1 (fr) Rechauffage d'un equipement aeronautique
CL2019003571A1 (es) Lipido que comprende ácido docosapentanoico. (divisional solicitud 3351-2016)
KR20180084962A (ko) 마스터 디스크 및 그 장착 방법과 분리 방법
GB201504523D0 (en) Combined shim and bore cooling assembly
ECSP18075709A (es) Composición para controlar fitoenfermedad y método para controlar fitoenfermedad